SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Natco Pharma receives Establishment Inspection Report for Chennai facility

25 Aug 2016 Evaluate

Natco Pharma has received successful Establishment Inspection Report (EIR) from the US Food and Drug Administration (FDA) for the inspection conducted, during the period February 8 - February 12, 2016, at its Chemical Division, Chennai, India (named Natco Organics, prior to amalgamation into the company).

The company has recently received successful EIR during the period February 29 to March 7, 2016 from the USFDA for the inspection conducted at its drug manufacturing facility in Kothur Village, Mahaboob Nagar District, Telangana.

Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.



Natco Pharma Share Price

1174.00 19.80 (1.72%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×